Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 70, Issue 6, 2011, Pages 1138-1143

  Mathian, Alexis ^a,b,c   Amoura, Zahir ^a,b,c   Adam, Estelle ^d   Colaone, Fabien ^d   Hoekman, Marco F M ^e   Dhellin, Olivier ^d   Vandepapelière, Pierre ^d   Haroche, Julien ^a   Piette, Jean Charles ^a   Lebon, Pierre ^f,g   Grouard Vogel, Géraldine ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d Neovacs SA   (France)

^e UTRECHT UNIVERSITY   (Netherlands)

^f HÔPITAL SAINT VINCENT DE PAUL   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERFERON ALPHA KINOID; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMOCYANIN; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ACTIVE; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, TRANSGENIC; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES;

EID: 79955863984     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.141101     Document Type: Article

References (34)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007 ; 369 : 587-96. (Pubitemid 46241445) (Pubitemid 46241445)
2. Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979 ; 301 : 5-8. (Pubitemid 9226519) (Pubitemid 9226519)
3. Hooks JJ, Jordan GW, Cupps T, et al. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 1982; 25 : 396-400. (Pubitemid 12158947) (Pubitemid 12158947)
4. Preble OT, Black RJ, Friedman RM, et al. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216 : 429-31. (Pubitemid 12076067) (Pubitemid 12076067)
5. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982 ; 25 : 401-6. (Pubitemid 12158948) (Pubitemid 12158948)
6. Lebon P, Lenoir GR, Fischer A, et al. Synthesis of intrathecal interferon in systemic lupus erythematosus with neurological complications. Br Med J (Clin Res Ed) 1983 ; 287 : 1165-7. (Pubitemid 13014045) (Pubitemid 13014045)
7. Dall'era MC, Cardarelli PM, Preston BT, et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005 ; 64 : 1692-7. (Pubitemid 41667141) (Pubitemid 41667141)
8. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100 : 2610-15. (Pubitemid 36297546) (Pubitemid 36297546)
9. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003 ; 197 : 711-23. (Pubitemid 36350866) (Pubitemid 36350866)
10. Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 2010 ; 6 : 339-47.
11. Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005 ; 23 : 307-36. (Pubitemid 40563172) (Pubitemid 40563172)
12. Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 2007 ; 316 : 359-86.
13. Chuntharapai A, Lai J, Huang X, et al. Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine 2001 ; 15 : 250-60. (Pubitemid 34587638) (Pubitemid 34587638)
14. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008 ; 117 : 244-79.
15. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009 ; 60 : 1785-96.
16. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007 ; 28 : 482-90. (Pubitemid 350087812) (Pubitemid 350087812)
17. Zagury D, Gallo RC. Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov Today 2004 ; 9 : 72-81. (Pubitemid 38169531) (Pubitemid 38169531)
18. Rad FH, Le Buanec H, Paturance S, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 2007 ; 104 : 2837-42. (Pubitemid 46327966) (Pubitemid 46327966)
19. Le Buanec H, Delavallée L, Bessis N, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 2006 ; 103 : 19442-7. (Pubitemid 46026050) (Pubitemid 46026050)
20. Zagury D, Le Buanec H, Mathian A, et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009 ; 106 : 5294-9.
21. Braun A, Kwee L, Labow MA, et al. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 1997 ; 14 : 1472-8. (Pubitemid 27481082) (Pubitemid 27481082)
22. Rubinstein S, Familletti PC, Pestka S. Convenient assay for interferons. J Virol 1981 ; 37 : 755-8. (Pubitemid 11188804) (Pubitemid 11188804)
23. Batteux F, Palmer P, Daëron M, et al. FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus. Eur Cytokine Netw 1999 ; 10 : 509-14.
24. Hochberg M C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 ; 40 : 1725.
25. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 ; 25 : 1271-7. (Pubitemid 13221242) (Pubitemid 13221242)
26. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992 ; 35 : 630-40.
27. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000 ; 81 : 2341-64.
28. Liew FY. T(H)1 and T(H)2 cells: a historical perspective. Nat Rev Immunol 2002 ; 2 : 55-60. (Pubitemid 37328776) (Pubitemid 37328776)
29. Palmer P, Tovey MG, Raschilas F, et al. Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors. Eur Cytokine Netw 2007 ; 18 : 108-14. (Pubitemid 47262365) (Pubitemid 47262365)
30. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004 ; 75 : 163-89. (Pubitemid 38174573) (Pubitemid 38174573)
31. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001 ; 14 : 778-809. (Pubitemid 32979631) (Pubitemid 32979631)
32. Kisand K, Link M, Wolff AS, et al. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 2008 ; 112 : 2657-66.
33. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006 ; 3 : e289.
34. Mathis D, Benoist C. Aire. Annu Rev Immunol 2009 ; 27 : 287-312.